drugset / Trial / NCT05293236
ApTOLL for the Treatment of COVID-19
Phase 1
Terminated
5 enrolled
Macarena Hernández Jiménez
Centro para el Desarrollo Tecnológico Industrial · collab
RandomizedSequentialTriple-blindTreatment
Summary
There is a clear and urgent medical need of developing new medicinal products for COVID-19 since there are poor pharmacological tools to block the progression of patients to cytokine storm syndrome (CSS). To this aim, this Phase Ib clinical study (APTACOVID) pretends to determine whether ApTOLL, in combination with the standard of care, is safe and shows any biological effect) in those patients infected with SARS-CoV-2 who are not developed CSS yet.
Timeline
- Start
- 2022-01-14
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Outcome
Outcome not reported
Stopped: “Lack of patients due to reduced incidence in the COVID-19 infected population in Spain”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ApTOLL | Aptamer | 0.05 mg/kg | Intravenous |
| Subject | ApTOLL | Aptamer | 0.1 mg/kg | Intravenous |
| Subject | ApTOLL | Aptamer | 0.2 mg/kg | Intravenous |